top of page
iStock-1324402385.jpg

RESURGE THERAPEUTICS

Pioneering Transformative Drug Delivery Solutions for Urology

We are a team of experts in drug delivery, engineering, clinical and business leadership.  Through collaboration with leading urologists and clinicians we are rethinking what is possible in treating large unmet urological conditions with localized drug delivery.  Our lead product is a local drug delivery therapy for treatment of lower urinary tract symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia.  

enlarged prostate recolored.jpg

BPH

Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia, BPH, is a common condition that affects aging men.  The prostate enlarges with age and compresses the urethra which results in urination challenges.  Left untreated it may lead to bladder or kidney problems. Approximately 40 million men in the US have BPH.  Current treatments include includes oral medications with limited efficacy and side effects or invasive and painful surgical procedures.

iStock-1022148436.jpg

OUR TECHNOLOGY

Advanced Drug Delivery Solutions

Innovation in local drug delivery is at the core of what we do at Resurge Therapeutics.  Our main goal is finding ways of delivering drugs to more efficiently treat local diseases without the side effects and compliance requirements of oral and systemic medications.  Locally administered drugs also serve as an alternative to more invasive surgical interventions.

ABOUT US

Resurge Therapeutics is founded and led by an experienced 

drug delivery and urology expert team.

NEWS
 

Resurge Therapeutics Compelling 6-Month Results Demonstrate Improvement in Patient Symptoms with Prostate Drug Delivery Platform

San Jose, CA, April 29, 2025 – Resurge Therapeutics, a privately-held urology biotechnology company, announced that 6-month results from the initial dose cohort human study of the Resurge drug delivery platform demonstrated improvements in patient lower urinary tract symptoms and flow rate outcomes, key goals for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).  The data were highlighted in a poster presented by Flavio Ordones, MD, that was awarded best presentation in the BPH New Technology Session at the American Urology Association (AUA) Annual Meeting, held April 26-29, 2025 in Las Vegas.   

iStock-501948853.jpg

Resurge Therapeutics mission is to provide transformative drug delivery solutions for urology.

2355 Paragon Drive Suite F

San Jose, CA 95131

contact@resurgetherapeutics.com

©2025 by Resurge Therapeutics.

bottom of page